Michael Savona, MD, professor of medicine and cancer biology, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, discusses phase 3 trial ASCERTAIN for the treatment of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). ASCERTAIN involves a combination of oral decitabine and cedazuridine compared to intravenous administration of decitabine alone. To date, the median follow up is two years, and the study still has not met median overall survival, so Dr. Savona is excited about the future of the study.
- Patients with a history of a hematologic malignancy who survive #COVID-19 infection have similar immune responses a… https://t.co/AHnuRwuR84
- Clarity on Disparity: Black patients with acute myeloid #leukemia (#AML) under the age of 60 have a 27% higher risk… https://t.co/3eU0hdWeCI
- During #ASH20, the @AML_Hub was pleased to speak to Uwe Platzbecker, University of Leipzig Medical Center, about th… https://t.co/SsP7pVq4Zu
- Discontinuation of eculizumab is feasible and safe in patients with atypical hemolytic uremic syndrome, particularl… https://t.co/IHfAzMciYP
- If you have been affected by #AML, you're not alone. Speak to your doctor, a specialist nurse, or your local suppor… https://t.co/VdZTU6wfdZ
- Presented by @CLachowiez at #ASH20: Adding venetoclax to fludarabine, cytarabine, granulocyte-colony stimulating fa… https://t.co/toeBzhm8GQ
- In his latest Editor’s Corner, Ari Giagounidis, MD, surveyed international hematologists about the rules regarding… https://t.co/Tz3KVsZd70
- In case you missed it ? Take a look at this animated video by Christine Spencer, Diwakar Davar and the @aml_hub whi… https://t.co/z9WY4303Qg
- Brain Drain: Among 509 patients with COVID-19 treated within a hospital network in Chicago, 82.3% had neurologic sy… https://t.co/IDl4swCL4o
- Combined p53 activation, through MDM2 inhibition, and BRD4-directed BET inhibition demonstrates encouraging preclin… https://t.co/Gmu0RdouH9
- In November 2020, eprenetapopt (APR-246) received @US_FDA Fast Track designation for the treatment of AML. Read mor… https://t.co/rb6a6uGnEm
- Results from the phase Ib/II study evaluating the safety, recommended phase II dose, and efficacy of eprenetapopt +… https://t.co/cI0xBbUQqP
- The co-chairs of this year’s #ASH20 Special Symposium on Quality, Sarah H. O’Brien, MD, and @NTConnell invited trai… https://t.co/fteIt4A2yW
- Achievement of measurable residual disease negativity is associated with significant improvements in survival in pa… https://t.co/brl9CVlqmg
- ?In case you missed it ? Residual circulating tumor DNA as a prognostic biomarker in patients with AML/MDS ??… https://t.co/pPsT4SLpTO
- In an analysis of data from the first 250 patients enrolled in the @ASHCollab COVID-19 Registry for Hematology, res… https://t.co/L6TEcSPngt
- RT @JNCI_Now: Survivors of childhood acute myeloid leukemia are at increased risk of long-term neurocognitive and psychosocial impairment c…
- The just-published mid-January Annual Meeting Edition features highlights from #ASH20, a look at doctor-patient gif… https://t.co/R12xbz7wt3
- NEWS | @US_FDA clears IND application for the engineered hematopoietic stem cell therapy, VOR33, which is being inv… https://t.co/uOP30JXmOs
- In case you missed it ? The @AML_Hub provided a summary of the explorative study evaluating the impact of NPM1mut M… https://t.co/ze9o0LqHRm
- #leusm https://t.co/4K792rG6u4
- In case you missed it ? The spectrum of clonal hematopoiesis: a summary of @DrKTakahashi, @MDAndersonNews’s Meet th… https://t.co/iYGOujUfLB
- Latest data from venetoclax plus HMAs for specific AML subpopulations. Read more here: https://t.co/U2l3FO0vJB… https://t.co/vsWSCABtwM
- RT @Anand_88_Patel: In Blood Cancer Journal Dr. Daver et al discuss the rapidly growing (and increasingly complex) landscape of therapies i…
- Progress for All: The gap in health outcomes among racial and ethnic groups shrunk from 1990 to 2016, according to… https://t.co/qJFmWvWGV3
- Written in @BloodJournal: A new AI-based technique was able to establish correlations between genetic and morpholog… https://t.co/q3pCfY2UVc
- ? It's not too late to sign-up for the AML Hub newsletter! Sign up today to get the latest news and expert intervie… https://t.co/650sVU4dma
- Why is self-advocacy so important for someone diagnosed with #AML? @KNOW_AML ambassador Stacey Koleszar from… https://t.co/ihuPIhwTEQ
- A new study published in Science Translational Medicine suggests a simple agent, sodium bicarbonate, could boost T-… https://t.co/T5gYPmrJG2
- “I tell [the junior faculty I mentor], ‘You’re doing good, quality science, so the grants will come. Don’t let the… https://t.co/Uc8rJrSeqo
- The Clot Thickens: Researchers reviewing data from patients enrolled in Danish medical registries found that patien… https://t.co/C5t4K1xShT
- At a list price of $270,000, the cost of anti-von Willebrand factor immunoglobulin fragment caplacizumab outweighs… https://t.co/hrbd33jPfF
- Congratulations to our Koichi Takahashi, M.D., Ph.D., @DrKTakahashi, of @MDAndersonNews #Leukemia, for being select… https://t.co/yxuMvaSzrQ
- Symptoms of relapsed AML may be similar to your first AML diagnosis. Symptoms may include tiredness, breathlessness… https://t.co/Bvg508WiOZ
- During #ASH20, we spoke to Jeffrey Lancet from @MoffittNews. We asked, Why is genetic testing key following an acut… https://t.co/TK8613aR4v
- Would you like to learn more about measurable residual disease (MRD) and when it should be tested? Watch our video… https://t.co/KOM7XcEwBD
- During #ASH20, we spoke to @KNOW_AML ambassador Agnieszka Wierzbowska from the University of Lodz. We asked, What i… https://t.co/BtQcuOohh0
- RT @Coping_Cancer: Happy 60th Birthday to acute myeloid leukemia survivor, @EvanHandler! Read his story from Coping here: https://t.co/HPg…
- RT @LLSusa: Compassion, care and patience for yourself is key, and we are always here for you. ?? Learn more about our support resources f…
- RT @Ankus_ingh: Need help & support for Ryan's Bone Marrow transplant. Ryan is diagnosed with leukemia when he was 4 months old. He is figh…
- Proud to welcome the Philippines Acute #Leukemia & Lymphoma Network to the #KnowAML global network! This associatio… https://t.co/skLOE3nUky
- Relapsed AML can happen any time after treatment. It can occur several months to years after initial treatment. For… https://t.co/9bA6dlU3RQ
- RT @AcuteLeuk: .@LeukaemiaCareUK is hosting a webinar for those affected by acute #leukaemia looking at survivorship on and long-term effec…
- During #ASH20, @KNOW_AML was pleased to speak to Ann-Kathrin Eisfeld @OSUCCC_James, about the impact of race on tre… https://t.co/NjU9P30FaL
- RT @BTMPublicPolicy: Listen to @MDAndersonNews's @CLachowiez speak on relapsed AML treatment strategies, via @KNOW_AML. https://t.co/JivRnz…
- During #ASH20, we spoke to @CLachowiez from @MDAndersonNews about treatment strategies used in relapsed acute myelo… https://t.co/4LjSgZMSEn
- RT @MDAndersonNews: Our cancer patients depend on blood and platelet donations, and right now our need for type O blood donations is especi…
- RT @doctorpemm: Wishing each of you a happy, healthy week filled w/innovation, prosperity & discovery on behalf of our patients with cancer…
- RT @MissionBio: Join us on Nov 9 to hear from two experts in the field of hematology, Dr. Michael Andreeff @MDAndersonNews and Dr. Peter Va…
- RT @gotoPER: Join our #ASH20 FSS Individualizing MF and PV Treatment program with Program Chair Srdan Verstovsek, MD, to keep up to date wi…
- RT @HelixBioPharma: Congrats! @MDAndersonNews Keep up the good work! Thanks to CAR T cell therapy, patients with lymphoma and leukemia have…
- RT @practiceupdate: Leukemic Evolution of Polycythemia Vera and Essential Thrombocythemia. Commentary by Srdan Verstovsek MD @MDAndersonNe…
- RT @VJHemOnc: Did you miss out on the #AML Sessions - venetoclax-based regimens? You can still watch @Daver_Leukemia, Courtney DiNardo, Ma…
- RT @VJHemOnc: ?Don't forget to check out our #AML Sessions w/ @Daver_Leukemia, Courtney DiNardo, Marina Konopleva & Andrew Wei! Now availa…
- RT @power4patients: Which #AML mutations can affect prognosis and treatment? @Daver_Leukemia of @LeukemiaMDA explains. #leusm #FLT3 #IDH1…
- RT @MDAndersonNews: “With immunotherapy, we are trying to harness or reinvigorate the immune system so that it recognizes and attacks the c…
- RT @achlcme: YOUR path, YOUR rules! This enhanced digital algorithm combines stepwise practical guidance with evidence-based education on t…
- RT @yazan_14: Honored to be presenting my first ASH oral presentation!!!. special thanks to @jaltmanmd & @bpromd for their mentorship. @McG…
- RT @ASCO_pubs: Mutant IDH1 inhibitor ivosidenib plus azacitadine was well tolerated in patients with IDH1-mutated newly-diagnosed acute mye…
- RT @doctorpemm: ???Our group’s new paper led by Dr Montalban-Bravo & @garciamanero ?? Clinical Outcomes and Influence of Mutation Clonal Do…
